Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 17NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 213Carcinoma, Non-Small-Cell Lung 148Lung Neoplasms 128Lymphoma 119Prostatic Neoplasms 115Leukemia 102Ovarian Neoplasms 100Central Nervous System Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Colorectal Neoplasms 89Head and Neck Neoplasms 87Sarcoma 84Multiple Myeloma 80Squamous Cell Carcinoma of Head and Neck 73Rectal Neoplasms 62Leukemia, Myeloid, Acute 62Carcinoma, Ovarian Epithelial 61Uterine Cervical Neoplasms 60Neoplasm Metastasis 59Brain Neoplasms 57Colonic Neoplasms 56Fallopian Tube Neoplasms 53Astrocytoma 53Lymphoma, Large B-Cell, Diffuse 50Glioblastoma 49Burkitt Lymphoma 47Urinary Bladder Neoplasms 46Neuroblastoma 44Melanoma 44Hodgkin Disease 44

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interventional × Cognition Disorders × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡